Perspective Therapeutics Files Q2 2024 10-Q
Ticker: CATX · Form: 10-Q · Filed: Aug 13, 2024 · CIK: 728387
Sentiment: neutral
Topics: 10-Q, financials, medical-devices
TL;DR
Perspective Therapeutics 10-Q filed: Financials updated, Cesium-131 biz details, notes & preferred stock info. #MedTech
AI Summary
Perspective Therapeutics, Inc. (formerly Isoray, Inc.) filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates, including information related to its Cesium-131 business and various financial instruments like promissory notes and preferred stock. The company is based in Seattle, WA, and operates in the surgical and medical instruments sector.
Why It Matters
This filing provides investors with the latest financial health and operational status of Perspective Therapeutics, crucial for understanding its market position and future prospects.
Risk Assessment
Risk Level: medium — The company has a history of name changes and operates in a specialized medical device sector, which can involve significant regulatory and market risks.
Key Numbers
- 2024-06-30 — Reporting Period End (Financial data is as of this date.)
- 2024-08-13 — Filing Date (Date the 10-Q was submitted to the SEC.)
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Filer
- Isoray, Inc. (company) — Former company name
- 20240630 (date) — Reporting period end date
- 20240813 (date) — Filing date
- Seattle, WA (location) — Company headquarters
- Cesium-131 (product) — Company business segment
FAQ
What were the key financial highlights for Perspective Therapeutics in the quarter ending June 30, 2024?
The 10-Q filing for the period ending June 30, 2024, provides detailed financial statements, but specific dollar amounts for revenue, net income, or loss are not explicitly listed in the provided header information.
What is the company's primary business focus as indicated in the filing?
The company is listed under Standard Industrial Classification code 3841 for Surgical & Medical Instruments & Apparatus, and the filing mentions the 'Cesium131BusinessMember'.
Has the company undergone any name changes?
Yes, the company was formerly known as Isoray, Inc. (name change effective 20181231) and IsoRay, Inc. (name change effective 20050805), and prior to that, CENTURY PARK PICTURES CORP (name change effective 19920703).
What types of financial instruments are mentioned in the filing?
The filing references 'PromissoryNoteMember', 'SeriesBConvertiblePreferredStockMember', and 'PublicOfferingMember' related to financial activities.
Where is Perspective Therapeutics, Inc. located?
The company's business and mailing address is listed as 2401 ELLIOTT AVENUE, SUITE 320, SEATTLE, WA 98121.
Filing Stats: 4,442 words · 18 min read · ~15 pages · Grade level 17.5 · Accepted 2024-08-13 16:04:53
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
Filing Documents
- catx-20240630.htm (10-Q) — 1614KB
- catx-ex10_1.htm (EX-10.1) — 203KB
- catx-ex10_2.htm (EX-10.2) — 196KB
- catx-ex31_1.htm (EX-31.1) — 15KB
- catx-ex31_2.htm (EX-31.2) — 15KB
- catx-ex31_3.htm (EX-31.3) — 15KB
- catx-ex32.htm (EX-32) — 13KB
- 0000950170-24-096148.txt ( ) — 8041KB
- catx-20240630.xsd (EX-101.SCH) — 1313KB
- catx-20240630_htm.xml (XML) — 1148KB
Financial Statements
Financial Statements 1 Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 (unaudited) 2 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 (unaudited) 3 Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and six months ended June 30, 2024 and 2023 (unaudited) 4 Notes to the Unaudited Condensed Consolidated Financial Statements 5 Item 2
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 27 Item 4
Controls and Procedures
Controls and Procedures 27 PART II OTHER INFORMATION Item 1
Legal Proceedings
Legal Proceedings 28 Item 1A
Risk Factors
Risk Factors 28 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3 Defaults Upon Senior Securities 28 Item 4 Mine Safety Disclosures 28 Item 5 Other Information 28 Item 6 Exhibits 29
Signatures
Signatures 30 iii Table of Contents
- FINA NCIAL INFORMATION
PART I - FINA NCIAL INFORMATION
- FIN ANCIAL STATEMENTS
ITEM 1 - FIN ANCIAL STATEMENTS Perspective Therapeutics, Inc. and Subsidiaries Condensed Consolid ated Balance Sheets (In thousands, except shares and par value data) June 30, December 31, 2024 2023 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 252,004 $ 9,238 Short-term investments 40,865 - Accounts receivable, net of allowance for doubtful accounts: 2024 - $ 606 ; 2023 - $ 650 142 1,165 Prepaid expenses and other current assets 1,226 1,133 Current assets held for sale, discontinued operations - 5,301 Total current assets 294,237 16,837 Noncurrent assets: Property and equipment, net 14,747 5,576 Right-of-use asset, net 2,019 747 Restricted cash 182 182 Intangible assets, in-process research and development 50,000 50,000 Goodwill 24,062 24,062 Other assets, net 672 487 Total assets $ 385,919 $ 97,891 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 6,127 $ 6,909 Lease liability 720 46 Accrued personnel expenses 2,309 3,588 Note payable 54 49 Deferred Income (Note 3) 1,400 - Current liabilities of discontinued operations - 5,072 Total current liabilities 10,610 15,664 Noncurrent liabilities: Lease liability 1,450 780 Note payable 1,651 1,676 Deferred Income (Note 3) 26,600 - Deferred tax liability 4,592 4,592 Other noncurrent liabilities 19 - Total liabilities 44,922 22,712 Commitments and contingencies (Note 10) Stockholders' equity: Preferred stock, $ 0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible preferred stock; no shares issued and outstanding as of June 30, 2024 and December 31, 2023 - - Common stock, $ 0.001 par value; 750,000,000 shares authorized; 67,425,167 and 28,180,985 shares issued and outstanding as of June 30, 2024 and December 31, 2023, resp